Drugmakers must sell established time-release drug when mergers overlap, Hoffman says

When two merging drugmakers both make certain time-released “complex” drugs, the US Federal Trade Commission believes the established drug, and not the drug in the research and development pipeline, must be divested, the acting director of the FTC’s bureau of competition has said.

Get unlimited access to all Global Competition Review content